Jennifer Ann Woyach MD

PubMed

• 2 citations
  Targeting WDR5/ATAD2 signaling by the CK2/IKAROS axis demonstrates therapeutic efficacy in T-ALL.
  Qi Han, Yan Gu, Huimin Xiang, Linyao Zhang, Yan Wang
  Blood. 2025-03-27
• Long-read single-cell RNA sequencing enables the study of cancer subclone-specific genotypes and phenotypes in chronic lymphocytic leukemia.
  Gage S Black, Xiaomeng Huang, Yi Qiao, Philip Moos, Deepa Sampath
  Genome Research. 2025-03-19
• Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL.
  Adam S Kittai, Ying Huang, Sarah Miller, John N Allan, Seema A Bhat
  Blood Cancer Journal. 2025-02-20

Journal Articles

• Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia  
  Jennifer Woyach, MD, Cancer Discovery
• Ibrutinib and Aspergillus: A Btk-Targeted Risk  
  Jennifer Woyach, MD, Blood

Abstracts/Posters

• The Protein Kinase C Inhibitor MS-553 for the Treatment of Chronic Lymphocytic Leukemia
  Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocy...
  Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Role of Mutant p53 in the Progression of Chronic Lymphocytic Leukemia
  Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (_ 70 Years...
  Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy
  Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Selinexor Combined with Ibrutinib Demonstrates Tolerability and Efficacy in Advanced B-Cell Malignancies: A Phase I Study
  Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (C...
  Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL
  Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia
  Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study
  Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Ibrutinib Treatment in CLL Patients Improves T Cell Function and Blinatumomab Redirected Cytotoxicity
  Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• LC-Facseq: A Novel Method for Detecting Rare Resistant Clones in Leukemia
  Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• MRD Testing to Guide Treatment Decisions in CLL 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Response Comes of Age in Chronic Lymphocytic Leukemia 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (_ 70 Years... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Acalabrutinib with obinutuzumab (Ob) in treatment-naive (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Three-year follow-up. 
  2019 ASCO Annual Meeting - 6/1/2019
• Mutations in the Ras Pathway in Pre-Treatment Chronic Lymphocytic Leukemia Are Associated with VH1-69: Linking B-Cell Receptor Stereotypy to Downstream Signaling Events 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all